Current status of gene therapy for pancreatic cancer

Current Surgery

Volumn 61, Issue 1, 2004, Pages 84-92

  Ramírez, Pedro J ^a   Vickers, Selwyn M ^a,b  

^a Kentucky   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

And therapy; Gene; Oncology; Pancreas

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BETA GLOBIN; CANCER VACCINE; CYTOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; GANCICLOVIR; GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LENTIVIRUS VECTOR; LIPOSOME; MONOCLONAL ANTIBODY; NAKED DNA; ONCOPROTEIN; ONYX 015; PARVOVIRUS VECTOR; PROTEIN P15; PROTEIN P16; PROTEIN P53; RECOMBINANT DNA; RETROVIRUS VECTOR; SMAD4 PROTEIN; THYMIDINE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; GENE TECHNOLOGY; GENE THERAPY; HISTORY OF MEDICINE; HUMAN; MOLECULAR BIOLOGY; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; PANCREAS CANCER; PATHOGENESIS; REVIEW; SUICIDE GENE THERAPY; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

EID: 0742268064     PISSN: 01497944     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cursur.2003.07.023     Document Type: Article

References (72)

1. Neoptolemos J.P. Cunningham D. Freiss H. et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives Ann Oncol 14 2003 675-692
2. el-Rayes B.F. Shileds A.F. Viatkevicius V. et al. Developments in the systemic therapy of pancreatic cancer Cancer Invest 21 2003 73-86
3. Bramhall S. Dunn J. Neoptolemos J.P. Epidemiology of pancreatic cancer Berger H.G. Warshaw A. Carr-Locke D.L. et al. The Pancreas 1998 889-906 Blackwell ScientificBoston, MA
4. Blaese R. Culver K. Miller A. et al. T lymphocyte directed gene therapy for ADA-SCID: initial trial results after 4 years Science 270 1995 475-480
5. Hecht J.R. Bedford R. Abbruzzese J.L. et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma Clin Cancer Res 9 2003 555-561
6. Mulvihill S. Warren R. Venook A. et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial Gene Ther 8 2001 308-315
7. Sakorafas G.H. Pancreatic cancer Kuzrock R. Talpaz M. Molecular biology in cancer medicine 2nd ed 1999 393-409 Martin Dunitz LtdLondon
8. Lowy D.R. Willumsen B.M. Function and regulation of ras Annu Rev Biochem 62 1993 851-891
9. Halloran C.M. Ghaneh P. Neoptolemos J.P. et al. Gene therapy for pancreatic cancer-current and prospective strategies Surg Oncol 9 2000 181-191
10. Freiss H. Gaussmann M. Buchler M.W. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers Int J Pancreatol 11 1997 43-52
11. Buchler M. Kubel R. Klapdor R. et al. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494: results from a multicentric phase I-II trials Beger H.G. Buehler M. Schulz G. et al. Cancer Therapy 3241 1989 SpringerBerlin
12. Sakorafas G.H. Tsiotos G. Molecular biology of pancreatic cancer. Potential clinical implications Biodrugs 15 2001 439-452
13. Lane D.P. p53 guardian of the genome Nature 358 1992 15-16
14. Barton C.M. Staddon S.L. Hughes C.M. et al. Abnormalities of p53 tumour suppressor gene in human pancreatic cancer Br J Cancer 64 1991 1076-1082
15. Kern S.E. Kinzler K.W. Bruskin A. et al. Identification of p53 as sequence-specific DNA-binding protein Science 252 1991 1708-1711
16. Casey G. Yamanaka Y. Freiss H. et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis Cancer Lett 69 1993 151-160
17. Nakamori S. Yashima K. Murakami Y. et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma Jpn J Cancer Res 86 1995 174-181
18. Humphreys M.J. Greenhalf W. Neoptolemos J.P. et al. The potential for gene therapy in pancreatic cancer Int J Panc 26 1999 5-21
19. Caldas C. Hahn S.A. da Costa L.T. et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat Genet 8 1994 27-32
20. Naumann M. Savitskaia N. Eilert C. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors Gastroenterology 110 1996 1215-1224
21. Hahn S.A. Schutte M. Hoque A.T.M.S. et al. DPC4, a candidate tumor suppressor geneat 18q21.1 Science 271 1996 350-353
22. Schutte M. Hruban R.H. Hedrick L. et al. DPC4 in various tumor types Cancer Res 56 1995 2527-2530
23. Rozenblum E. Schutte M. Goggins M. et al. Tumor suppressive pathways in pancreatic cancer Cancer Res 57 1997 1731-1734
24. Gustin A. Pederson L. Miller R. Chan C. Vickers S.M. Application of molecular biology studies to gene therapy treatment strategies World J Surg 26 2002 854-860
25. Yamanaka Y. Freiss H. Buchler M. et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage Cancer Res 53 1993 5289-5296
26. Kobrin M.S. Yamanaka Y. Freiss H. et al. Aberrant exprression of the type I fibroblast growth factor receptor in human pancreatic adenocarcinoma Cancer Res 53 1993 4741-4744
27. Leung H.Y. Gullick W.J. Lemoine N.R. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer Int J Cancer 59 1994 667-675
28. Lemoine N.R. Hughes C.M. Barton C.M. The epidermal growth factor receptor in human pancreatic cancer J Pathol 166 1992 7-12
29. Yamanaka Y. Freiss H. Kobrin M.S. et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma Hum Pathol 24 1993 1127-1134
30. Kore M. Chandrasekar B. Yamanaka Y. et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha J Clin Ivest 90 1992 1352-1360
31. Kobrin M.S. Funatomi H. Freiss H. et al. Induction and expression of heparin-binding FGF-like growth factor in human pancreatic cancer Biochem Biophys Res Commun 202 1994 1705-1709
32. Kore M. Role of growth factors in pancreatic cancer Surg Oncol Clin N Am 7 1998 25-41
33. Friess H. Yamanaka Y. Büchler M. et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival Gastroenterology 105 1993 1846-1856
34. Derynek R. Zhang Y. Feng X.H. Smads: transcriptional activators of TGF-beta responses Cell 95 1998 737-740
35. Kleeff J. Maruyama H. Freiss H. et al. Smad 6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer Biochem Biophys Res Commun 255 1999 268-273
36. Kleeff J. Ishiwata T. Maruyama H. et al. The TGF-beta signalling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer Oncogene 18 1999 5363-5372
37. Hata A. Shi Y. Massague J. TGF-beta signalling and cancer: structural and functional consequences of mutations in Smads Mol Med Today 4 1998 257-262
38. Freiss H. Kleeff J. Korc M. et al. Molecular aspects of pancreatic cancer and future perspectives Dig Surg 16 1999 281-290
39. Curiel D. The development of conditionally replicative adenoviruses for cancer therapy Clin Cancer Res 6 2000 3395-3399
40. Yang L. Hwang R. Pandit L. et al. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir Ann Surg 224 1996 405-414
41. Markowitz D. Goff S. Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids J Virol 62 1988 1120-1124
42. Burns J.C. Friedman T. Driever W. et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titre and efficient gene transfer into mammalian and non-mammalian cells Proc Nat Acad Sci 90 1993 8033-8037
43. Wesseling J.G. Yamamoto M. Adachi Y. et al. Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma Cancer Gene Ther 8 2001 990-996
44. Mena I. Fischer J.R. Gebhard J. et al. Coxsackievirus infection of the pancreas: evaluation of receptor expression, pathogenesis, and immunopathology Virology 271 2000 276-288
45. Dmitriev I. Krasnykh V. Miller C.R. et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism J Virol 72 1998 9706-9713
46. Krasnykh V. Mikheeva G.V. Douglas J.T. et al. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism J Virol 70 1996 6839-6846
47. Carter P.J. Samulski R.J. Adeno associated viral vectors as gene delivery vehicles Int J Mol Med 6 2000 17-27
48. Kasuya H. Mizuno M. Yoshida J. et al. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy J Surg Oncol 74 2000 214-218
49. Peng L. Sidner R.A. Bochan M.R. et al. Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene J Surg Res 69 1997 193-198
50. Schmid R.M. Weidenbach H. Yamaguchi H. et al. Direct gene transfer into the rat pancreas using DNA-liposomes Eur J Clin Invest 28 1998 220-226
51. Cheng L. Ziegelhoffer P.R. Yang N.S. In vivo promoter activity and transgene activity in mammalian tissues evaluated by tissue bombardment Proc Natl Acad Sci USA 90 1993 4455-4459
52. Clary B.M. Lyerly K. Gene therapy and pancreatic cancer Surg Oncol Clin N Am 7 1998 217-249
53. Funatomi H. Ikatura I. Pastan I. et al. Amphiregullin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targetted therapy Int J Cancer 72 1997 512-517
54. Smith J.P. Verderame M.F. Zagon I.S. Antisense oligonucleotides to gastrin inhibits growth of human pancreatic cancer cells Cancer Lett 35 1999 107-112
55. Sklar M. Thompson E. Welsh M. et al. Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells Mol Cell Biol 11 1991 3699-3710
56. Lang D. Miknyoczki S.J. Huang L. et al. Stable reintroduction of wild-type p53 (MTmp53ts) causes induction of apoptosis and neurocrine-like differentiation in human ductal pancreatic cancer cells Oncogene 16 1998 1593-1602
57. Ghaneh P. Humphreys M. Greenhalf W. et al. p53 and p16 gene therapy results in killing of pancreatic cells Br J Surg 85 1998 1555
58. Bouvet M. Bold R.J. Lee J. et al. Adenovirus-mediated wild-type p53 tumour suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer Ann Surg Oncol 5 1998 681-688
59. Hwang R.F. Gordon E.M. Anderson W.F. et al. Gene therapy for primary and metastatic pancreatic cancer with intraperitoneal retroviral vector bearing the wild-type p53 gene Surgery 124 1998 143-151
60. Ghaneh P. Humphreys M. Greenhalf W. et al. p53 and p16 gene therapy results in killing of pancreatic cells Br J Surg 85 1998 1555
61. Kobayashi S. Shirasawa H. Sashiyama H. et al. p16INK4a expression adenovirus vector to suppress pancreas cancer cell proliferation Clin Cancer Res 5 1999 4182-4185
62. Schwartze-Waldhoff I. Klein S. Hintelmann A. et al. Suppression of tumoric genicity in colorectal and pancreatic cancer cells by reconstitution of DPC4/SMAD4 is associated with expression changes of invasion, metastasis, and angiogenesis regulators Gastroenterology 16 1999 pG2193
63. DiMaio J. Clary B. Via D. et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo Surgery 116 1994 205-213
64. Yang L. Chiang Y.W. Lenz H.J. et al. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based therapy of human gastrointestinal tumor cells Hum Gene Ther 9 1998 719-728
65. Rigg A.S. Lemoine N.R. Genetic prodrug activation therapy for pancreatic cancer Ann N Y Acad Sci 880 1999 319-325
66. Kimura M. Tagawa M. Takenaga K. et al. Loss of tumorigenicity of human pancreatic carcinoma cells engineered to produce interlekin- or interleukin-4 in nude mice: a potentiality for cancer gene therapy Cancer Lett 128 1998 47-53
67. Clary B.M. Coveney E.C. Philip R. et al. Inhibition of established pancreatic cancers following specific active immunotherapy with inteleukin-2 gene-transduced tumour cells Cancer Gene Ther 4 1997 97-104
68. Gjertsen M. Saeserdal I. Thorsby E. et al. Characterization of immune responses in pancreatic carcinoma patients affect mutant p-21 ras peptide vaccination Br J Cancer 74 1996 1829-1833
69. Rigg A.S. Scarpa A. Pandha H.S. et al. Gene therapy for pancreatic cancer Ital J Gastroenterol Hepatol 30 1998 462-466
70. Jaffee E.M. Abrams R. Cameron J. et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumour cells transfected with GM-CSF gene for treatment of pancreatic adenocarcinoma Hum Gene Ther 9 1998 1951-1971
71. Bramhall S.R. The matrix metalloproteinases and their inhibitors in pancreatic cancer Int J Pancreatol 21 1997 1-12
72. Bloomston M. Shaffi A. Zervos E.E. et al. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis J Surg Res 102 2002 39-44